Small molecule · preclinical metabolic research
What is 5-Amino-1MQ?
5-Amino-1MQ is short for 5-amino-1-methylquinolinium. It is a small molecule studied for inhibiting nicotinamide N-methyltransferase, or NNMT. It is frequently grouped with peptides in catalogues, but chemically it is not a peptide.
How does 5-Amino-1MQ work?
NNMT is an enzyme involved in nicotinamide metabolism and cellular methylation-related processes. Researchers investigate how inhibiting it changes metabolic pathways and tissue behaviour. [1]
What does the research show?
A 2018 study tested small-molecule NNMT inhibitors, including 5-Amino-1MQ, in mice with diet-induced obesity. A 2024 experiment investigated body composition, glucose-related measurements and liver changes in obese mice. [1]
What the evidence does not establish
Both examples concern preclinical models. Changes in mouse fat mass or glucose regulation do not establish effective human weight management, a safe human amount, or long-term clinical benefit.
Safety questions to discuss
A biological target can be scientifically interesting while a product remains inadequately characterised for personal use. Ask whether a claim is based on an actual human trial or only an animal experiment. [2]
Frequently asked questions
Is 5-Amino-1MQ a peptide?
No. It is a small-molecule NNMT inhibitor.
Do the cited mouse studies establish a safe human protocol?
No. Animal dosing and outcomes cannot be converted into a personal treatment plan.
Sources and further reading
- Small-molecule NNMT inhibitors in diet-induced obese mice, 2018
- NNMT inhibition and metabolic dysfunction — mouse study, 2024
These are selected sources, not a systematic review. Check publication dates, study methods and the exact substance tested. Artwork does not establish clinical benefit.